CLPTM1L

Across TCGA pan-cancer cohorts, CLPTM1L Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CLPTM1L data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CLPTM1L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLPTM1L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and ESCA are the cancer types where CLPTM1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	24	view →
UCEC	OS	Median	All	1.000	0.864	.018	22	view →
ESCA	DFS	Median	II,III,IV	0.180	0.525	.015	12	view →
LUSC	OS	Median	II,III,IV	0.259	0.742	.021	12	view →
LIHC	OS	Median	II,III,IV	0.118	0.716	.003	12	view →
STAD	OS	Median	All	0.111	0.538	.028	3	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CLPTM1L–ACC (DFS)

Open the ACC breakdown →